Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[68Ga]Ga-anti-integrin peptide
- Development stage
- Preclinical
- Lead developer
- CancerThera
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
[68Ga]Ga-anti-integrin peptide (specifically [68Ga]Ga-DOTA-C6-anti-integrin peptide) is a novel radiolabeled peptide-based diagnostic imaging agent developed by researchers in Brazil, including the State University of Campinas (UNICAMP) and the Santa Casa de São Paulo School of Medical Sciences, in collaboration with the CancerThera research center. The agent consists of an anti-integrin peptide conjugated to the chelator DOTA via a 3-aminocaproic acid (C6) spacer and radiolabeled with the positron-emitting radionuclide gallium-68 ([68Ga]). It selectively targets integrin αvβ3, a cell surface receptor overexpressed in glioblastoma and other highly angiogenic tumors. Preclinical studies demonstrate that the tracer successfully crosses the blood-brain barrier, accumulates in glioblastoma cells, and is cleared via the kidneys, highlighting its potential as a PET/CT imaging probe for tumor detection, boundary definition, and treatment monitoring.
- Other names
- 68Ga-DOTA-C6-anti-integrin peptideDOTA-C6-anti-integrin peptideDOTA-C-6-anti-integrin peptideDOTA-C 6-anti-integrin peptide[68Ga]Ga-DOTA-C6-anti-integrin[68Ga]Ga-DOTA-C6-anti-integrin peptide
02
Targets
αVβ3 (Integrin αVβ3)
Beyond the preview
Go deeper on [68Ga]Ga-anti-integrin peptide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [68Ga]Ga-anti-integrin peptide.